The recombinant ligands CCL22 and CCL2 in this study were used in concentrations of 50 ng/mL, and it is not clear from our data what concentration will be required in vivo to efficiently reroute immune cells towards tumor sites. This evidence concerns the gene CCL2 and neoplasm.